Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
BL-G Internal request In response to the FDA approval of sacituzumab govitecan-hziy for the treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor, the panel requested the addition of sacituzumab govitecan for this indication. External request Submission request from Gilead Sciences, Inc. (05/15/21): consider recommending the preferred use of sacituzumab govitecan-hziy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.	Based on the review of the data in the noted references and the recent FDA approval, the panel consensus was to include sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. This is a category 2A, Other recommended regimen. Loriat Y, et al. TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI) [abstract]. Ann Oncol 2020;31:Abstract LBA24.	23	0	3	5